

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Noxafil

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address: Address:		
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable	e):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following qu	n for this patient that may support a	approval. Please answer the
Q1. Specify the prescriber's specialty.		
☐ Hematology		
☐ Oncology		
☐ Infectious Disease		
Other (please specify)		
Q2. Please indicate location of administration.		
Home		
☐ Long Term Care (LTC) facility		
Physician office (drug from office stock - buy and bill)		
☐ Physician office (drug from pharmacy with a prescription	on)	
Q3. Is Noxafil being used for primary prophylaxis?		
Yes □ No		
	f	alla colla a
Q4. If being used for primary prophylaxis, please indicate i	_	ollowing
Acute leukemia undergoing induction/consolidation che	• •	
Allogeneic hematopoietic transplant while receiving im	munosuppressive therapy	
Other (please specify)		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Noxafil

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
Q5. If being used for treatment, does the patient h	nave a fungal infection resistant to other formulary agents?
Q6. If being used for treatment, was infectious dis	seases (ID) consulted on the case?
Q7. Additional Comments	
Prescriber Signature	
-	ning above, I certify that applying the standard review timeframe may
	e or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document